Paris, je stent: Fierce's 2013 EuroPCR coverage

With another EuroPCR drawn to a close, the world's medical device companies have packed up their denervators, scaffolds and balloons and returned to Dublin, St. Paul and Boston. In case you missed any of last week's data dumps and unveilings, we kept tabs on all the goings on of Europe's largest cardiovascular get-together.

Below, we've collected each of our daily roundups from the conference, plus a few break-out stories on in-the-spotlight technologies.

Day One: Medtronic, J&J's Cordis headline EuroPCR 2013, plus news on renal denervation, heart valves and refractory angina devices from Edwards Lifesciences ($EW), Veryan Medical and Neovasc.

Day Two: Boston Scientific, Elixir make waves at EuroPCR 2013, with more updates on dissolvable vascular scaffolds and coronary bifurcation treatment from Medtronic ($MDT) and St. Jude Medical ($STJ).

Day Three: St. Jude, CardioKinetix tout impressive data at EuroPCR 2013, also featuring studies on hypertension and drug-eluting balloons from Boston Scientific ($BSX) and Medtronic.

Day Four: Covidien, Kona Medical trumpet new tech at EuroPCR, plus results on drug-eluting stents and ultrasound-based renal denervation from Tryton Medical and Elixir Medical.

Boston Scientific's strong results fuel hope for renal denervation success: Boston Scientific made a splash when it spent $425 million on 2012 Fierce 15 winner Vessix Vascular last year, and now, with strong interim data for its newly acquired renal denervation system, the company has a shot to compete for market share in the soon-to-boom space.

Stentys self-apposing cardiac stent gets the job done at one year: Stentys is celebrating more positive clinical data stemming from the use of its self-apposing stent to treat acute heart attacks. The French company, citing results from its APPOSITION III trial, noted a 2% mortality rate after one year and a 1.3% rate of new heart attacks.

-- Damian Garde (email | Twitter)

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.